Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by THOMAS W BURKE and LOIS M RAMONDETTA.
THOMAS W BURKE
Connection Strength
1.176
LOIS M RAMONDETTA
  1. Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma. Cancer. 2009 May 01; 115(9):1867-74.
    View in: PubMed
    Score: 0.340
  2. Mixed choriocarcinoma in a postmenopausal patient. Int J Gynecol Cancer. 2002 May-Jun; 12(3):312-6.
    View in: PubMed
    Score: 0.209
  3. A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium. Gynecol Oncol. 2013 May; 129(2):304-9.
    View in: PubMed
    Score: 0.110
  4. A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma. Int J Gynecol Cancer. 2011 Apr; 21(3):517-22.
    View in: PubMed
    Score: 0.097
  5. In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell lines. Cancer Chemother Pharmacol. 2008 Aug; 62(3):483-9.
    View in: PubMed
    Score: 0.077
  6. Practice patterns of SGO members for stage IIIA endometrial cancer. Gynecol Oncol. 2005 Jul; 98(1):77-83.
    View in: PubMed
    Score: 0.065
  7. A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed m?llerian tumors with evaluation of potential molecular targets. Gynecol Oncol. 2003 Sep; 90(3):529-36.
    View in: PubMed
    Score: 0.057
  8. Treatment of uterine papillary serous carcinoma with paclitaxel. Gynecol Oncol. 2001 Jul; 82(1):156-61.
    View in: PubMed
    Score: 0.049
  9. Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer. Clin Cancer Res. 2000 Jan; 6(1):278-84.
    View in: PubMed
    Score: 0.045
  10. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010 Dec 01; 116(23):5415-9.
    View in: PubMed
    Score: 0.023
  11. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. Gynecol Oncol. 2005 May; 97(2):489-96.
    View in: PubMed
    Score: 0.016
  12. Heterogeneity of stage IIIA endometrial carcinomas: implications for adjuvant therapy. Int J Gynecol Cancer. 2005 May-Jun; 15(3):510-6.
    View in: PubMed
    Score: 0.016
  13. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma. Gynecol Oncol. 2004 Oct; 95(1):32-6.
    View in: PubMed
    Score: 0.015
  14. Malignant mixed M?llerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys. 2004 Mar 01; 58(3):786-96.
    View in: PubMed
    Score: 0.015
  15. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol. 2003 Dec; 91(3):463-9.
    View in: PubMed
    Score: 0.015
  16. PTEN expression in tamoxifen-associated endometrial cancers. Anticancer Res. 2002 Sep-Oct; 22(5):2945-8.
    View in: PubMed
    Score: 0.013
  17. Metastatic uterine papillary serous carcinoma to the pericardium. Gynecol Oncol. 2001 Oct; 83(1):135-7.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.